Monitoring release of ketoprofen enantiomers from biodegradable poly(d,l-lactide-co-glycolide) injectable implants

International Journal of Pharmaceutics

Volumn 337, Issue 1-2, 2007, Pages 102-108

  Wang, S H ^a,b   Liang, Z H ^c   Zeng, S ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

^c ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

Biodegradable injectable implants; d,l PLG; Enantiomer; Ketoprofen; RP HPLC; Stereoselective release

Indexed keywords

1 METHYL 2 PYRROLIDINONE; KETOPROFEN; POLYGLACTIN;

ARTICLE; BIODEGRADABLE IMPLANT; DRUG RELEASE; ENANTIOMER; IN VITRO STUDY; PH; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SUSTAINED RELEASE PREPARATION;

ABSORBABLE IMPLANTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BUFFERS; CALIBRATION; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMPOUNDING; DRUG IMPLANTS; HYDROGEN-ION CONCENTRATION; INJECTIONS; KETOPROFEN; LACTIC ACID; POLYGLYCOLIC ACID; POLYMERS; PYRROLIDINONES; REPRODUCIBILITY OF RESULTS; SOLUBILITY; SOLVENTS; STEREOISOMERISM; TIME FACTORS;

EID: 34248586328     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.12.031     Document Type: Article

References (22)

1. Alvarez C., Torrado J.J., and Cadorniga R. Stereoselective drug release from ketoprofen and ricobendazole matrix tablets. Chirality 11 (1999) 611-615
2. Ameyibor E., and Stewart J.T. HPLC determination of ketoprofen enantiomers in human serum using a nonporous octadecylsilane 1.5 microns column with hydroxypropyl beta-cyclodextrin as mobile phase additive. J. Pharm. Biomed. Anal. 17 (1998) 83-88
3. Duddu S.P., Vakilynejad M., and Jamali F. Stereoselective dissolution of propranolol hydrochloride from hydroxypropylmethylcellulose matrices. Pharm. Res. 10 (1993) 1648-1653
4. Dunn, R.L., Tipton, A.J., Southard, G.L., Rogers, J.A., 1989. US Patent 5,077,049.
5. Eliaz R.E., Wallach D., and Kost J. Delivery of soluble tumor necrosis factor receptor from in-situ forming PLGA implants: in-vivo. Pharm. Res. 17 (2000) 1546-1550
6. Janjikhel P.K. Stereospecific formulation and characterization of sustained release ibuprofen microspheres. J. Microencapsul. 14 (1997) 409-426
7. Janjikhel R.K., and Adeyeye C.M. Dissolution of ibuprofen enantiomers from coprecipitates and suspensions containing chiral excipients. Pharm. Dev. Technol. 4 (1999) 9-17
8. Onishi H., Takahashi M., and Machida Y. PLGA implant tablet of ketoprofen: comparison of in vitro and in vivo releases. Biol. Pharm. Bull. 28 (2005) 2011-2015
9. Park T.G. Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition. Biomaterials 16 (1995) 1123-1130
10. Qiu Y., Hui H.W., and Cheskin H. Formulation development of sustained-release hydrophilic matrix tablets of zileuton. Pharm. Dev. Technol. 2 (1997) 197-204
11. Shah N.H., Railkar A.S., Chen F.C., Tarantino R., Kumar S., Murjani M., Palmer D., Infeld M.H., and Malick A.W. A biodegradable injectable implant for delivering micro and macromolecules using poly(lactic-co-glycolic acid) (PLGA)copolymer. J. Control. Release 27 (1993) 139-147
12. Shameem, M., Lee, H., Deluca, P.P., 1999. A short-term (accelerated release) approach to evaluate peptide release from PLGA depot formulations. AAPS Pharmsci., 1, article 7 (http://www.pharmsci.org).
13. Siewert M., Dressman J., Brown C.K., and Shah V.P. FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms. AAPS PharmSciTech. 4 (2003) E7
14. Simo C., Gallardo A., Parejo C., San Roman J., Barbas C., and Cifuentes A. Monitoring ibuprofen enantiomers released from polymeric systems. Eur. J. Pharm. Sci. 16 (2002) 75-82
15. Solinis M.A., Lugara S., Calvo B., Hernandez R.M., Gascon A.R., and Pedraz J.L. Release of salbutamol sulfate enantiomers from hydroxypropylmethylcellulose matrices. Int. J. Pharm. 161 (1998) 37-43
16. Solinis M.A., Cruz Y., Calvo B., Hernandez R.M., Gascon A.R., Goni I., Gurruchaga M.D., and Pedraz J.L. Release of salbutanmol sulphate and ketoprofen enantiomers from matrices containing HPMC and cellulose derivatives. Chirality 14 (2002) 806-813
17. Solinis M.A., Cruz Y., Hernandez R.M., Gascon A.R., Calvo B., and Pedraz J.L. Release of ketoprofen enantiomers from HPMC K100M matrices-diffusion studies. Int. J. Pharm. 239 (2002) 61-68
18. Suedee R., Srichana T., and Chotivatesin R. Enantioselective release of controlled delivery granules based on molecularly imprinted polymers. Drug Deliv. 9 (2002) 19-30
19. Sun Q., and Olesik S.V. Chiral separation by simultaneous use of vancomycin as stationary phase chiral selector and chiral mobile phase additive. J. Chromatogr. B Biomed. Sci. Appl. 745 (2000) 159-166
20. Vakily M., and Jamali F. Human pharmacokinetics of tiaprofenic acid after regular and sustained release formulations: lack of chiral inversion and stereoselective release. J. Pharm. Sci. 83 (1994) 495-498
21. Vakily M., Pasutto F.M., Daneshtalab M., and Jamali F. Inclusion complexation of heptakis(2,6-di-ethyl)-β-cyclodextrin with tiaprofenic acid: pharmacokinetic consequences of a pH-dependent release and stereoselective dissolution. J. Pharm. Sci. 84 (1995) 1014-1019
22. Wang S.H., and Zeng S. Stereorelease of enantiomers from chiral formulation. Chin. Pharm. J. 40 (2005) 10-12